Hanmi Pharmaceutical Earnings Strength Signals Obesity Growth Hanmi Pharmaceutical is rated Buy as strong revenue and 59.6% gross margin offset a 36% YoY operating profit drop; investors bet execution and partnerships will stabilize operating earnings. 2026년 09월 08일 English
Samsung C&T Net Profit Jumps Despite Revenue Growth: Insight Samsung C&T earns buying consensus as revenue and net profit rise, despite slightly weaker operating profit; targets imply meaningful upside if margins stabilize. 2026년 08월 27일 English
